FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362548761> ?p ?o ?g. }

• W4362548761 abstract "<div><p>Inflammation is a cancer hallmark. NSAIDs improve overall survival (OS) in certain cancers. Real-world studies explored here whether NSAIDs improve non–small cell lung cancer (NSCLC) OS. Analyses independently interrogated clinical databases from The University of Texas MD Anderson Cancer Center (MDACC cohort, 1987 to 2015; 33,162 NSCLCs and 3,033 NSAID users) and Georgetown-MedStar health system (Georgetown cohort, 2000 to 2019; 4,497 NSCLCs and 1,993 NSAID users). Structured and unstructured clinical data were extracted from electronic health records using natural language processing (NLP). Associations were made between NSAID use and NSCLC prognostic features (tobacco use, gender, race, and body mass index, BMI). NSAIDs were statistically significantly (<i>P</i> < 0.0001) associated with increased NSCLC survival (5-year OS 29.7% for NSAID users vs. 13.1% for nonusers) in the MDACC cohort. NSAID users gained 11.6 months over nonusers in 5-year restricted mean survival time. Stratified analysis by stage, histopathology, and multicovariable assessment substantiated benefits. NSAID users were pooled independent of NSAID type and by NSAID type. Landmark analysis excluded immortal time bias. Survival improvements (<i>P</i> < 0.0001) were confirmed in the Georgetown cohort. Thus, real-world NSAID usage was independently associated with increased NSCLC survival in the MDACC and Georgetown cohorts. Findings were confirmed by landmark analyses and NSAID type. The OS benefits persisted despite tobacco use and did not depend on gender, race, or BMI (MDACC cohort, <i>P</i> < 0.0001). These real-world findings could guide future NSAID lung cancer randomized trials.</p>Significance:<p>NLP and real-world studies conducted in large cohorts explored whether NSAIDs improved survival across NSCLC stages, histopathology, gender, smoking history, or demographic groups. A statistically significant association between NSAID use and NSCLC survival was found. This provides a rationale for future NSAID randomized NSCLC trials.</p></div>" @default.
• W4362548761 created "2023-04-06" @default.
• W4362548761 creator A5027438799 @default.
• W4362548761 creator A5027998671 @default.
• W4362548761 creator A5034362700 @default.
• W4362548761 creator A5035961942 @default.
• W4362548761 creator A5037218810 @default.
• W4362548761 creator A5041570474 @default.
• W4362548761 creator A5065839430 @default.
• W4362548761 creator A5080648304 @default.
• W4362548761 creator A5083247969 @default.
• W4362548761 creator A5084086047 @default.
• W4362548761 creator A5086058658 @default.
• W4362548761 creator A5091028729 @default.
• W4362548761 date "2023-04-04" @default.
• W4362548761 modified "2023-10-18" @default.
• W4362548761 title "Data from Real-world Studies Link NSAID Use to Improved Overall Lung Cancer Survival" @default.
• W4362548761 doi "https://doi.org/10.1158/2767-9764.c.6550998" @default.
• W4362548761 hasPublicationYear "2023" @default.
• W4362548761 type Work @default.
• W4362548761 citedByCount "0" @default.
• W4362548761 crossrefType "posted-content" @default.
• W4362548761 hasAuthorship W4362548761A5027438799 @default.
• W4362548761 hasAuthorship W4362548761A5027998671 @default.
• W4362548761 hasAuthorship W4362548761A5034362700 @default.
• W4362548761 hasAuthorship W4362548761A5035961942 @default.
• W4362548761 hasAuthorship W4362548761A5037218810 @default.
• W4362548761 hasAuthorship W4362548761A5041570474 @default.
• W4362548761 hasAuthorship W4362548761A5065839430 @default.
• W4362548761 hasAuthorship W4362548761A5080648304 @default.
• W4362548761 hasAuthorship W4362548761A5083247969 @default.
• W4362548761 hasAuthorship W4362548761A5084086047 @default.
• W4362548761 hasAuthorship W4362548761A5086058658 @default.
• W4362548761 hasAuthorship W4362548761A5091028729 @default.
• W4362548761 hasBestOaLocation W43625487612 @default.
• W4362548761 hasConcept C121608353 @default.
• W4362548761 hasConcept C126322002 @default.
• W4362548761 hasConcept C143998085 @default.
• W4362548761 hasConcept C201903717 @default.
• W4362548761 hasConcept C2776256026 @default.
• W4362548761 hasConcept C2780221984 @default.
• W4362548761 hasConcept C71924100 @default.
• W4362548761 hasConcept C72563966 @default.
• W4362548761 hasConceptScore W4362548761C121608353 @default.
• W4362548761 hasConceptScore W4362548761C126322002 @default.
• W4362548761 hasConceptScore W4362548761C143998085 @default.
• W4362548761 hasConceptScore W4362548761C201903717 @default.
• W4362548761 hasConceptScore W4362548761C2776256026 @default.
• W4362548761 hasConceptScore W4362548761C2780221984 @default.
• W4362548761 hasConceptScore W4362548761C71924100 @default.
• W4362548761 hasConceptScore W4362548761C72563966 @default.
• W4362548761 hasLocation W43625487611 @default.
• W4362548761 hasLocation W43625487612 @default.
• W4362548761 hasOpenAccess W4362548761 @default.
• W4362548761 hasPrimaryLocation W43625487611 @default.
• W4362548761 hasRelatedWork W1971557041 @default.
• W4362548761 hasRelatedWork W2087279843 @default.
• W4362548761 hasRelatedWork W2410418192 @default.
• W4362548761 hasRelatedWork W2745006705 @default.
• W4362548761 hasRelatedWork W293724110 @default.
• W4362548761 hasRelatedWork W3032856175 @default.
• W4362548761 hasRelatedWork W3117997272 @default.
• W4362548761 hasRelatedWork W3216318198 @default.
• W4362548761 hasRelatedWork W4322492676 @default.
• W4362548761 hasRelatedWork W605648234 @default.
• W4362548761 isParatext "false" @default.
• W4362548761 isRetracted "false" @default.
• W4362548761 workType "article" @default.